XML 68 R34.htm IDEA: XBRL DOCUMENT v2.4.0.8
INCOME TAXES (Tables)
12 Months Ended
Dec. 31, 2013
Income Tax Disclosure [Abstract]  
Schedule of components of income tax expense
The provisions for income tax expense (benefit), to the Company's wholly-owned subsidiary, MethylGene US Inc., are as follows (in thousands):
 
Year ended December 31,
Current:
2013
 
2012
Federal
$
(23
)
 
$
30

State

 
9

Canada

 

Total current tax expense (benefit)
$
(23
)
 
$
39

Schedule of Effective Income Tax Reconciliation
The differences between the effective income tax rate and the statutory tax rates during the years ended 2013 and 2012 are as follows (in thousands):
 
Year Ended December 31,
 
2013
 
2012
Net loss before tax
$
(52,882
)
 
$
(20,247
)
Statutory combined US federal and state tax rate (2012 - statutory combined Canadian federal and provincial tax rate)
39.83
%
 
26.90
%
Statutory federal and provincial taxes
$
(21,063
)
 
$
(5,446
)
Increase (decrease) in taxes recoverable resulting from:
 
 
 
Effect of change in valuation allowance
8,537

 
5,145

Non-deductible stock-based compensation
1,085

 
539

Non-deductible warrant expenses for tax purposes
8,403

 

Tax credits not taxable in Quebec
(96
)
 
(70
)
Share issue costs - temporary difference
(184
)
 
(183
)
Share issue costs - permanent difference
206

 

Effect of foreign jurisdiction tax expense

 
39

Differential in income tax rates of foreign subsidiary
3,059

 

Other differences
30

 
15

Income tax expense (benefit)
$
(23
)
 
$
39

Schedule of deferred tax
The following table summarizes the significant components of our deferred tax assets (in thousands):
 
DECEMBER 31,
Deferred tax assets
2013
 
2012
Assets
 
 
 
Tangible and intangible depreciable assets
$
874

 
$
853

Manufactured drug product inventory to be used in research
1,459

 
757

Provisions
93

 
30

Financing fees
445

 
628

Net operating loss carry forwards
13,099

 
6,883

Scientific research and experimental development expenditures
5,766

 
4,245

Deferred tax assets
21,736

 
13,396

Valuation allowance
(21,736
)
 
(13,396
)
Net deferred tax assets
$

 
$

Schedule of expiration of NOLs
The NOLs expire as follows (in thousands):
 
US
 
Canada
 
Federal
 
State
 
Federal
 
Provincial
Expires in:
 
 
 
 
 
 
 
2030
$

 
$

 
$
5,907

 
$
5,984

2031

 

 
7,059

 
7,066

2032

 

 
12,371

 
12,495

2033
2,838

 
2,919

 
18,717

 
19,467

 
$
2,838

 
$
2,919

 
$
44,054

 
$
45,012

Schedule of reconciliation of the beginning and ending gross amounts of unrecognized tax positions
A reconciliation of the beginning and ending gross amounts of Canadian unrecognized tax positions adopted by the Company are as follows (in thousands):
 
Federal
 
Provincial
 
December 31,
 
December 31,
 
2013
 
2012
 
2013
 
2012
Unrecognized tax positions, beginning of year
$
159

 
$
157

 
$
5

 
$
3

Gross decrease — current period tax positions

 

 

 

Gross increase — current period tax positions

 
2

 

 
2

Gross decrease — prior period tax positions
(48
)
 

 

 

Gross increase — prior period tax positions
18

 

 
18

 

Unrecognized tax positions, end of year
$
129

 
$
159

 
$
23

 
$
5